Halozyme Therapeutics has developed a technology to replace intravenous infusions

A new technology developed by Halozyme Therapeutics, makes injecting biologic drugs under the skin possible rather than with intravenous infusions. Now the American pharmaceutical company, Eli Lilly and Company, is licensing the technology from the company.

Halozyme develops synthetic enzymes on a technology platform which is called Enhanze that adapts the enzyme hyaluronidase. This enzyme acts by degrading hyaluronan, a naturally occurring gel-like substance in skin and cartilage, and also in tumor cells. When formulated for drug delivery, hyaluronidase can help biologics and small-molecule drugs spread quickly in the body under the condition of injecting under the skin.

Halozyme points out that hyaluronidase can also be set to operate under certain conditions, such as when patients show specific physical traits, or when it is necessary to minimize the side effects. The degradation of hyaluronan is temporary, which allows restoration of the degraded cell matrices, according to the company.

Besides, Halozyme is also developing a cancer drug code-named PEGPH20 designed to break up solid-tumor micro-environments protected by high levels of hyaluronan. PEGPH20 is applied in early and medium stage of clinical trials as a treatment for gastric, pancreatic, and non-small cell lung cancer.

The deal between Eli Lilly and Company and Halozyme could bring the latter biotechnology company about $825 million.

Cusabio is a company specialized in production of high quality products for gene, protein, antibody, ELISA kit, raw material for production of diagnostic kit, drug residues, food safety small molecules & other small molecules. Feel free to contact Cusabio if you need. Here is its website: www.cusabio.com